AI assistant
Sending…
Aquestive Therapeutics, Inc. — Director's Dealing 2018
Dec 4, 2018
32552_dirs_2018-12-04_335af566-2852-4856-b7bb-232ecd776dfe.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aquestive Therapeutics, Inc. (AQST)
CIK: 0001398733
Period of Report: 2018-11-30
Reporting Person: Kendall Keith J (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-11-30 | Common Stock | M | 14572 | — | Acquired | 635711 | Direct |
| 2018-11-30 | Common Stock | F | 7177 | $8.59 | Disposed | 628534 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-11-30 | Restricted Stock Unit | $ | M | 14572 | Disposed | Common Stock (14572) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on August 31, 2018, subject in each case to Mr. Kendall's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof.
More from Aquestive Therapeutics, Inc.
Annual Report
2026
Apr 24
Regulatory Filings
2026
Mar 30
Board/Management Information
2026
Mar 20
Investor Presentation
2026
Feb 26
Regulatory Filings
2026
Feb 2
Regulatory Filings
2026
Jan 21
Regulatory Filings
2026
Jan 9
Director's Dealing
2025
Dec 5
Director's Dealing
2025
Dec 4
Regulatory Filings
2025
Nov 17